DCGI says WHO drew premature link between children deaths in Gambia, Maiden Pharma Cough Syrups

Published On 2022-12-18 09:40 GMT   |   Update On 2022-12-18 09:40 GMT

Calling out the World Health Organisation (WHO) for "prematurely" blaming an Indian company for the deaths without verification, India's drug regulator claimed that the samples of Maiden Pharma's cough syrups suspected of being linked to deaths of children in Gambia were not contaminated glycol (DEG) and ethylene glycol (EG), and have been found to be of standard quality.In wake of...

Login or Register to read the full article

Calling out the World Health Organisation (WHO) for "prematurely" blaming an Indian company for the deaths without verification, India's drug regulator claimed that the samples of Maiden Pharma's cough syrups suspected of being linked to deaths of children in Gambia were not contaminated glycol (DEG) and ethylene glycol (EG), and have been found to be of standard quality.

In wake of this confirmation given by the Drug Controller General of Indian (DCGI), Maiden Pharmaceuticals Ltd on Friday said that it will seek clearance to re-open its factory as the Indian government laboratory found nothing wrong in samples taken from syrups namely Promethazine Oral Solution BP, KOFEXMALIN Baby Cough Syrup, MaKOFF Baby Cough syrup and MaGrip n Cold Syrup.

For more details, check out the link given below:

DCGI Calls Out WHO For 'Prematurely' Blaming Maiden Pharma For Cough Syrup Linked Deaths In Gambia


Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News